RS20050450A - 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists - Google Patents

2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists

Info

Publication number
RS20050450A
RS20050450A YUP-2005/0450A YUP20050450A RS20050450A RS 20050450 A RS20050450 A RS 20050450A YU P20050450 A YUP20050450 A YU P20050450A RS 20050450 A RS20050450 A RS 20050450A
Authority
RS
Serbia
Prior art keywords
aminocarbonyl
adenosine diphosphate
receptor antagonists
quinoline compounds
compounds
Prior art date
Application number
YUP-2005/0450A
Other languages
English (en)
Inventor
Judi Bryant
Brad Buckman
Imadul Islam
Raju Mohan
Michael Morrissey
Guo Ping Wei
Wei Xu
Shendong Yuan
Original Assignee
Schering Aktiengesellschaft,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft, filed Critical Schering Aktiengesellschaft,
Publication of RS20050450A publication Critical patent/RS20050450A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Jedinjenje sledeće formule: Gde su m, n, R1, R2, R3, R4 i R6 ovde opisani, korisna kao inhibitori adenozin difosfata krvne pločice. Ovde su takođe opisani farmaceutski sastavi koji sadrže ova jedinjenja, postupci upotrebe ovih jedinejnja kao antitrombotičnih sredstava i postupci sintetizovanja ovih jedinjenja.
YUP-2005/0450A 2002-12-11 2003-12-09 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists RS20050450A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43279202P 2002-12-11 2002-12-11
PCT/US2003/039079 WO2004052366A1 (en) 2002-12-11 2003-12-09 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists

Publications (1)

Publication Number Publication Date
RS20050450A true RS20050450A (en) 2007-08-03

Family

ID=32507994

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0450A RS20050450A (en) 2002-12-11 2003-12-09 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists

Country Status (23)

Country Link
US (2) US7056923B2 (sr)
EP (1) EP1578423B1 (sr)
JP (1) JP4662777B2 (sr)
KR (1) KR20050085580A (sr)
CN (1) CN1747732A (sr)
AP (1) AP2005003363A0 (sr)
AT (1) ATE477800T1 (sr)
AU (1) AU2003297763A1 (sr)
BR (1) BR0317222A (sr)
CA (1) CA2507657C (sr)
DE (1) DE60333866D1 (sr)
EA (1) EA200500899A1 (sr)
EC (1) ECSP055912A (sr)
ES (1) ES2348942T3 (sr)
MX (1) MXPA05006302A (sr)
NO (1) NO20053335L (sr)
NZ (1) NZ540872A (sr)
OA (1) OA12970A (sr)
PL (1) PL377053A1 (sr)
RS (1) RS20050450A (sr)
UA (1) UA83648C2 (sr)
WO (1) WO2004052366A1 (sr)
ZA (1) ZA200505492B (sr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
ATE469157T1 (de) * 2003-10-21 2010-06-15 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
CA2619706A1 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity quinoline-based kinase ligands
DE102006020385A1 (de) * 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Verfahren und Vorrichtung zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
EP2148871A1 (en) * 2007-04-23 2010-02-03 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
CA2690243A1 (en) 2007-06-18 2008-12-24 Sanofi-Aventis Pyrrole derivatives as p2y12 antagonists
AR069494A1 (es) 2007-11-29 2010-01-27 Actelion Pharmaceuticals Ltd Derivados de acidos fosfonicos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
SG175075A1 (en) * 2009-04-08 2011-11-28 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as adp receptor antagonists
MX2011010811A (es) 2009-04-22 2011-10-28 Actelion Pharmaceuticals Ltd Derivados de tiazol y su uso como antagonistas del receptor p2y12.
CN102304108B (zh) * 2011-06-28 2013-11-06 中国药科大学 五元杂环双羰基衍生物及其抗多药耐药细菌上的用途
CN104151235B (zh) * 2014-08-07 2016-01-20 南阳师范学院 一种喹啉衍生物制备方法
MY193080A (en) 2016-09-22 2022-09-26 Idorsia Pharmaceuticals Ltd Crystalline forms
KR102510832B1 (ko) 2017-03-15 2023-03-15 이도르시아 파마슈티컬스 리미티드 P2y12 수용체 안타고니스트의 피하 투여
CN112062687B (zh) * 2020-09-02 2023-11-21 上海信谊万象药业股份有限公司 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法
CN112920181A (zh) * 2021-01-29 2021-06-08 中国医科大学 N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US60474A (en) * 1866-12-18 Pbtee chick
GB1334705A (en) 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
US4258192A (en) * 1977-12-16 1981-03-24 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
JPH05503300A (ja) 1990-11-15 1993-06-03 ペンタファルム　アクチェンゲゼルシャフト メタ置換フェニルアラニン誘導体
WO1994018185A1 (de) * 1993-02-10 1994-08-18 Pentapharm Ag Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren
KR0173034B1 (ko) 1995-04-28 1999-03-30 성재갑 선택적 트롬빈 억제제
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists

Also Published As

Publication number Publication date
NO20053335D0 (no) 2005-07-08
WO2004052366A1 (en) 2004-06-24
US20060122188A1 (en) 2006-06-08
ATE477800T1 (de) 2010-09-15
CN1747732A (zh) 2006-03-15
OA12970A (en) 2006-10-13
NO20053335L (no) 2005-09-07
AP2005003363A0 (en) 2005-09-30
AU2003297763A1 (en) 2004-06-30
EA200500899A1 (ru) 2006-02-24
CA2507657C (en) 2011-05-31
NZ540872A (en) 2007-08-31
ES2348942T3 (es) 2010-12-17
BR0317222A (pt) 2005-11-01
JP2006511519A (ja) 2006-04-06
JP4662777B2 (ja) 2011-03-30
KR20050085580A (ko) 2005-08-29
WO2004052366A9 (en) 2005-06-23
ZA200505492B (en) 2006-03-29
PL377053A1 (pl) 2006-01-23
ECSP055912A (es) 2005-11-22
DE60333866D1 (de) 2010-09-30
MXPA05006302A (es) 2005-08-29
US7084142B2 (en) 2006-08-01
EP1578423B1 (en) 2010-08-18
US7056923B2 (en) 2006-06-06
CA2507657A1 (en) 2004-06-24
US20040138229A1 (en) 2004-07-15
EP1578423A1 (en) 2005-09-28
UA83648C2 (ru) 2008-08-11

Similar Documents

Publication Publication Date Title
RS20050450A (en) 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
WO2002098856A3 (en) Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists
ES2154167A1 (es) Aminoderivados ciclicos antagonistas del receptor ccr-3.
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
AU2003228770A8 (en) Substituted pyrazolopyrimidines
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
DE602004021472D1 (en) Pyrimiidinverbindungen
WO2003086303A3 (en) Farnesoid x-activated receptor agonists
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
TR200302268T4 (tr) NOS inhibitörleri olarak yararlı N-heterosiklik türevler.
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
NO20055749L (no) Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
WO2003080631A3 (en) Plasma carboxypeptidase b inhibitors
DE60201074D1 (en) Pyrazolopyridinderivate
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren
MXPA05005340A (es) Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen.
MXPA05006587A (es) Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
MXPA05006530A (es) Derivados de 1-n-fenilamino-1h-imidazola como inhibidores aromatasa.
TNSN05161A1 (en) 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors